Dr. George Sahyoun holds a Bachelor’s degree in Molecular and Cellular Biology from the University of Kent at Canterbury, United Kingdom and a PhD in Cancer and Stem Cell research from the University of Bradford, United Kingdom. After completing his studies, Dr. Sahyoun worked as a researcher at the Institute of Pharmaceutical Innovation (IPI) in Bradford and then went on to specialize in inherited diseases and Metabolic Disorders on a clinical level at St. James Hospital, Leeds, United Kingdom.  He continued his training in Thessaloniki, Greece in the fields of Genetics and Histocompatibility at Eurogenetica Hospital and Papageorgiou Hospital respectively. 

Upon returning to Jordan in 2009, Dr. Sahyoun joined MedLabs where he set up the first full Newborn Screening program in Jordan, which received full CAP (College of American Pathologists) accreditation. Dr. Sahyoun then established the Molecular and Cytogenetics departments. Between 2009 and 2017 as Chief R&D officer, Dr. Sahyoun brought in new technologies to widen MedLabs test menu and better serve the community while providing the most accurate results to patients.  This began with the introduction of new platforms such as a second LC-MS/MS Tandem Mass Spectrometer and the Luminex (Bead technology). He currently is also Director of MedLabs’ Reference Laboratory’s Analytical Operations and Chief Scientific Officer at MedLabs. Dr. Sahyoun is a frequent speaker at local and international medical conferences and has delivered over 40 significant lectures across the region on the medical importance of neonatal screening.